0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TIGIT

TIGIT

Brief Information

Name:T cell immunoglobulin and ITIM domains
Target Synonym:V-Set And Immunoglobulin Domain Containing 9,Washington University Cell Adhesion Molecule,V-Set And Transmembrane Domain Containing 3,WUCAM,DKFZp667A205,FLJ39873,V-set and immunoglobulin domain-containing protein 9,TIGIT,VSIG9,T Cell Immunoreceptor With I
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

TIT-H5253-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

TIT-H82F1-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).

TIT-C52H7-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human CD155, Fc Tag (Cat. No. CD5-H5251) on Protein A Biosensor, can bind Canine TIGIT, His Tag (Cat. No. TIT-C52H7) with an affinity constant of 5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TIT-H5253-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) on Protein A Biosensor, can bind Human CD155, His Tag (Cat. No. CD5-H5223) with an affinity constant of 0.92 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

TIGIT,VSIG9,VSTM3

Background

TIGIT has been shown to be over expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TIL). Blockade of TIGIT led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells, which now make it be considered as an immune checkpoint. Recently, studies have shown anti-TIGIT antibody is promising to become a cancer immunotherapy. Our ELISA kit is designed to help the discovery of anti-TIGIT therapeutic antibody.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
JS-006 JS-006 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours Details
AB-308 AB-308 Phase 1 Clinical Arcus Biosciences Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
HB0030 HB0030 Details
IBI-939 IBI-939 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Lung Neoplasms Details
Domvanalimab AB-154 Phase 3 Clinical Arcus Biosciences Solid tumours; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
COM-902 COM-902 Phase 1 Clinical Compugen Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Lung Neoplasms Details
BMS-986207 BMS-986207 Phase 2 Clinical Bristol-Myers Squibb Company Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ASP-8374 ASP-8374; PTZ-201 Phase 1 Clinical Potenza Therapeutics, Astellas Pharma Inc Solid tumours Details
Tiragolumab RG-6058; MTIG-7192A; RO-7092284 Phase 3 Clinical F. Hoffmann-La Roche Ltd Liver Neoplasms; Solid tumours; Lymphoma, B-Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Multiple Myeloma; Esophageal Squamous Cell Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Adenocarcinoma Details
SEA-TGT SGN-TGT; SEA-TGT Phase 1 Clinical Seattle Genetics Skin Melanoma; Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Etigilimab OMP-313M32 Phase 2 Clinical Oncomed Pharmaceuticals Solid tumours; Neoplasm Metastasis Details
TJ-T6-M TJ-T6-M I-Mab Biopharma Co Ltd Details
EOS-448 EOS-448; EOS-884448 Phase 2 Clinical Iteos Hematologic Neoplasms; Neoplasms Details
AZD-2936 AZD-2936 Phase 2 Clinical Astrazeneca Plc Carcinoma, Non-Small-Cell Lung Details
Vibostolimab MK-7684; MK-7684A Phase 3 Clinical Merck Sharp & Dohme Corp Solid tumours; Hematologic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Gallbladder Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
Ociperlimab BGB-A1217 Phase 3 Clinical Beigene Ltd Solid tumours; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop